Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.

abstract：:In a prospective multicenter study 68 out of 158 patients with HIV infection and malignant lymphoma were assigned to a risk-adapted induction therapy using the following algorithm: High-risk patients fulfilled 2 of 3 criteria: T4 lymphocytes <50/microL; WHO activity index 3 or 4; pre-existing AIDS-defining opportunist...

journal_title：Leukemia & lymphoma

authors： Weiss R,Huhn D,Mitrou P,Nerl C,Schürmann D,Scheidegger C,Knauf W,Trenn G,Kronawitter U,Van Lunzen J,Arastéh K,Herbst H

更新日期：1998-03-01 00:00:00

abstract：:Therapy with an immunotoxin, anti-Tac(Fv)-PE38, which is a conjugate of the variable domains of an anti-Tac monoclonal antibody and Pseudomonas exotoxin, was reported to be useful for adult T cell leukemia (ATL) patients but a considerable amount of the immunotoxin is needed for the therapy and some side effects were ...

journal_title：Leukemia & lymphoma

authors： Ohno N,Kreitman RJ,Saito T,Masamoto I,Uozumi K,Hanada S,Takeuchi S,Furukawa T,Sumizawa T,Arima T,Akiyama S

更新日期：2002-04-01 00:00:00

abstract：:We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...

journal_title：Leukemia & lymphoma

authors： Chong EA,Svoboda J,Cherian S,Andreadis C,Downs LH,Zhuang H,Alavi A,Tsai DE,Schuster SJ

更新日期：2005-09-01 00:00:00

abstract：:Even though amphotericin B is associated with considerable hematological toxicity, this subject has been poorly studied. This retrospective cohort study assessed the incidence and predictors of hematological toxicity in patients treated with different amphotericin B formulations: amphotericin B deoxycholate (d-AmB), l...

journal_title：Leukemia & lymphoma

authors： Falci DR,da Rosa FB,Pasqualotto AC

更新日期：2015-01-01 00:00:00

abstract：:High dose cytosine arabinoside (ARA-C) has produced long term relapse free survival in 26% to 49% of patients when used as consolidation therapy of acute non-lymphocytic leukemia (ANLL) in first remission. However, the optimal consolidation regimen has not been defined. In this pilot study we attempted to confirm and ...

journal_title：Leukemia & lymphoma

authors： Stein RS,Greer JP,Flexner JM,Goodman S,Wolff SN

更新日期：1996-09-01 00:00:00

abstract：:Bone marrow toxicity is a great challenge for physicians treating patients with non-Hodgkin's lymphoma (NHL) and prescribed chemotherapy. Granulocyte colony-stimulating factor (G-CSF) prevents myelotoxicity, but the optimal timing and scheduling of G-CSF administration has not been ascertained. We investigated leukocy...

journal_title：Leukemia & lymphoma

authors： Sawada KI,Sato N,Kohno M,Hannda H,Yasukouchi T,Tanngo M,Hirayama A,Koike T

更新日期：1995-12-01 00:00:00

abstract：:Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...

journal_title：Leukemia & lymphoma

authors： Robak T,Góra-Tybor J,Tybor K,Jamroziak K,Robak P,Kordek R,Rieske P,Majos A,Urbańska-Ryś H

更新日期：2004-06-01 00:00:00

abstract：:Monoclonal proteins (paraproteins) may be detected in the sera in approximately 1% of the general population and are frequently associated with peripheral neuropathy. Paraproteinemic neuropathy (PPN) is most commonly associated with monoclonal gammopathy of undetermined significance, and may also occur in the context ...

journal_title：Leukemia & lymphoma

authors： Zivković SA,Lacomis D,Lentzsch S

更新日期：2009-09-01 00:00:00

abstract：:The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

journal_title：Leukemia & lymphoma

authors： Masdehors P,Merle-Béral H,Magdelénat H,Delic J

更新日期：2000-08-01 00:00:00

abstract：:Human herpes virus type 6 can reactivate in patients after allogeneic stem cell transplantation and has been associated with serious sequelae such as delayed engraftment and an increased risk of developing acute graft-versus-host disease (GVHD). This study investigated human herpes virus type 6 (HHV-6) reactivation wi...

journal_title：Leukemia & lymphoma

authors： Cirrone F,Ippoliti C,Wang H,Zhou XK,Gergis U,Mayer S,Shore T,van Besien K

更新日期：2016-11-01 00:00:00

abstract：:A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

journal_title：Leukemia & lymphoma

authors： Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

更新日期：2004-03-01 00:00:00

abstract：:Both Epstein-Barr virus (EBV) and the human T-cell leukemia virus I (HTLV-I) have been implicated in the generation of human lymphoproliferative disorders such as Burkitt's lymphoma, Hodgkin's disease (HD) and acute T-cell leukemia (ATL). In Hodgkin's disease EBV has been recently detected in Hodgkin's and Sternberg-R...

journal_title：Leukemia & lymphoma

authors： Tesch H,Jücker M,Krönke M,Diehl V

更新日期：1991-01-01 00:00:00

abstract：:The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplas...

journal_title：Leukemia & lymphoma

authors： Boddu P,Kantarjian H,Garcia-Manero G,Allison J,Sharma P,Daver N

更新日期：2018-04-01 00:00:00

abstract：:The quinazoline antifolate N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl)-L-glutamic acid (ZD1694; Tomudex) is a potent inhibitor of thymidylate synthase and causes cell death through disruption of DNA synthesis and repair by blocking the obligatory thymidine nucleotide synthesis....

journal_title：Leukemia & lymphoma

authors： Ek O,Reaman GH,Crankshaw DL,Chelstrom LM,Myers DE,Uckun FM

更新日期：1998-02-01 00:00:00

abstract：:Factors predictive for central nervous system (CNS) involvement at presentation were investigated in 152 patients with non-Hodgkin's lymphoma (NHL) except for lymphoblastic cell lymphoma and small noncleaved cell lymphoma. Twelve patients developed CNS involvement during their disease course. The incidence was 7.9% of...

journal_title：Leukemia & lymphoma

authors： Tomita N,Kodama F,Sakai R,Koharasawa H,Hattori M,Taguchi J,Fujita H,Tanabe J,Fujisawa S,Fukawa H,Harano H,Kanamori H,Miyashita H,Matsuzaki M,Ogawa K,Motomura S,Maruta A,Ishigatsubo Y

更新日期：2000-07-01 00:00:00

abstract：:JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in sp...

journal_title：Leukemia & lymphoma

authors： Menghrajani K,Boonstra PS,Mercer JA,Perkins C,Gowin KL,Weber AA,Mesa R,Gotlib JR,Wang L,Singer JW,Talpaz M

更新日期：2019-04-01 00:00:00

abstract：:We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p<0.05). Sixteen patients...

journal_title：Leukemia & lymphoma

authors： Wang JC,Chen C,Dumlao T,Naik S,Chang T,Xiao YY,Sominsky I,Burton J

更新日期：2008-12-01 00:00:00

abstract：:Tsg101 is a mouse tumor suppressor gene whose homozygous deletion produces transformation of NIH3T3 cells and leads to metastases in nude mice. The human homologue of the gene, TSG101, is localized in chromosome 11p15.1-p15.2. Reduced TSG101 expression may cause the defect of the cell cycle checkpoint that leads to ge...

journal_title：Leukemia & lymphoma

authors： Lin SF,Lin PM,Liu TC,Chang JG,Sue YC,Chen TP

更新日期：2000-02-01 00:00:00

abstract：:Bone marrow transplantation procedure has emerged as an effective treatment for hematological malignancies. However, recurrence of leukemia is still the major cause of treatment failure. Subsequent treatment in this category of patients, generally considered incurable, has not been yet standardized. At our institution...

journal_title：Leukemia & lymphoma

authors： Sica S,Salutari P,Di Mario A,D'Onofrio G,Etuk B,Leone G

更新日期：1994-09-01 00:00:00

abstract：:Expression of the intercellular adhesion molecule-1 (CD54) as well as the mutations of p53 gene were studied in childhood Burkitt's lymphoma (BL). Expression of CD54 was identified in 6 of 15 fresh BL cases. Mutations of p53 gene, analyzed by polymerase chain reaction-single stranded chain polymorphism followed by seq...

journal_title：Leukemia & lymphoma

authors： Kaneko H,Sugita K,Kiyokawa N,Iizuka K,Takada K,Saito M,Yoshimoto K,Itakura M,Kokai Y,Fujimoto J

更新日期：1996-05-01 00:00:00

abstract：:Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and...

journal_title：Leukemia & lymphoma

authors： Nagorsen D,Bargou R,Ruttinger D,Kufer P,Baeuerle PA,Zugmaier G

更新日期：2009-06-01 00:00:00

abstract：:Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residua...

journal_title：Leukemia & lymphoma

authors： Owen C,Christofides A,Johnson N,Lawrence T,MacDonald D,Ward C

更新日期：2017-12-01 00:00:00

abstract：:To better define the incidence and nature of secondary chromosome anomalies in mantle cell lymphoma (MCL) carrying the t(11:14)/BCL1 rearrangement, cytogenetic and fluorescence in situ hybridization studies (FISH) were performed in 42 patients (39 classical histology, 3 blastoid variant), using 6q21, 9p21/p16, 13q14, ...

journal_title：Leukemia & lymphoma

authors： Bigoni R,Cuneo A,Milani R,Roberti MG,Bardi A,Rigolin GM,Cavazzini F,Agostini P,Castoldi G

更新日期：2001-02-01 00:00:00

abstract：:Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reti...

journal_title：Leukemia & lymphoma

authors： Olnes MJ,Nicol T,Duncan M,Bohlman M,Erlich R

更新日期：2002-04-01 00:00:00

abstract：:Multiple myeloma (MM) often presents with unspecific symptoms and is challenging to diagnose. We performed this DSMM/EMN-analysis via test-(retro-) and validation (prospective) study to determine the time interval from the onset of first symptoms to the diagnosis of MM. The retrospective and prospective analyses were ...

journal_title：Leukemia & lymphoma

authors： Graziani G,Herget GW,Ihorst G,Zeissig M,Chaidos A,Auner HW,Duyster J,Wäsch R,Engelhardt M

更新日期：2020-04-01 00:00:00

abstract：:In this report, we present a patient with chronic myeloid leukemia (CML) in blastic phase who had two consecutive episodes of spontaneous regression back to chronic phase without chemotherapy. Although, spontaneous remission (SR) is well documented in acute leukemia, SR in CML blastic phase is extremely rare and to th...

journal_title：Leukemia & lymphoma

authors： Cağirgan S,Sencan M,Tombuloglu M,Ozdemir E,Hekimgil M,Büyükkeçeci F

更新日期：1998-04-01 00:00:00

abstract：:Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically. Conventional diagnostic radiology and computed tomography (CT) are generally unable to detect the differences between tumor tissue ...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Zompatori M,Bendandi M,Battista G,Fanti S,Barbieri E,Gherlinzoni F,Rimondi MR,Frezza G,Pisi P,Merla E,Gozzetti A,Canini R,Monetti N,Babini L,Tura S

更新日期：1996-06-01 00:00:00

abstract：:Primary hematolymphoid malignancies of the extrahepatic biliary tract are rare tumors. We report five cases of primary hematolymphoid malignancies involving the extrahepatic biliary tract. One is a granulocytic sarcoma of the extrahepatic bile duct, another is an extramedullary plasmacytoma of the gallbladder, and the...

journal_title：Leukemia & lymphoma

authors： Hwang DW,Lim CS,Jang JY,Lee SE,Yoon SO,Jeon YK,Uk Lee K,Kim SW

更新日期：2010-07-01 00:00:00

abstract：:Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

journal_title：Leukemia & lymphoma

authors： Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

更新日期：1993-05-01 00:00:00

abstract：:Although treatment of Hodgkin's disease has been extensively studied in the past, fewer clinical studies are being reported, despite the fact that the optimal therapy for each stage has not yet been established. The pathologic subtypes have not been officially changed for years, although lymphocyte-predominant disease...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1996-03-01 00:00:00